Startup Nation Central, a nonprofit that promotes the Israeli innovation ecosystem globally, has released its 2024 annual report titled THE POWER OF SCALE: Israeli Tech Global Edge. The report provides an in-depth analysis of the country’s tech landscape based on data and insights from its ecosystem business-engagement platform, Finder. Despite the ongoing war and local challenges, Israel’s tech ecosystem proved its resilience, evolving from a startup hub to a scale-up powerhouse with larger funding rounds, a growing number of mature companies, and a surge in acquisition-driven exits. Israel’s tech sector secured over $12 billion in private funding, achieved record M&A activity of $15.8 billion, and drove economic growth, with high-tech GDP rising by 2.2% even as the overall economy contracted. The report highlights Israel’s leadership in sectors like cybersecurity and its evolution into a scale-up powerhouse, marked by mature companies,… 

The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL®, indicated for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children two months and older. This milestone in regenerative medicine was developed and patented by Osiris Therapeutics (Osris), a venture founded by Kevin Kimberlin and Dr. Arnold Caplan, and first backed by Spencer Trask & Co. Kimberlin, who previously collaborated with Dr. Jonas Salk to develop the first FDA-approved cell-based immunotherapy, partnered with Dr. Caplan to conduct the first human clinical trials with mesenchymal stromal cells. This work was instrumental in establishing the safety and feasibility of MSC therapies, directly contributing to the development and eventual FDA approval of treatments like RYONCIL. To complete the necessary Phase 3 trials, Osiris licensed the intellectual property in exchange for milestone payments and royalties, and sold the product, originally called… 

IMPACT Therapeutics („IMPACT“), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib Capsules (???®?has received marketing authorization in China from National Medical Products Administration (NMPA) as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. Senaparib, discovered and developed by IMPACT, is a potent and novel PARP 1/2 inhibitor. Its distinctive molecular structure provides it with high in vitro and in vivo activity, exceptional target selectivity and wide safety window. The approval is based on FLAMES Study. The study is a randomized, double-blind, placebo-controlled, multicenter, phase III clinical study to evaluate the efficacy and safety of Senaparib as…